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The development of vaccines against AIDS has focused primarily on the viral envelope gene product and has been complicated by the emergence of neutralization escape mutants (10, 12, 14) as well as sequence variation in the envelope glycoprotein (40, 44) . Previous candidate vaccines that induced human immunodeficiency virus (HIV)-specific neutralizing antibodies in chimpanzees did not protect these animals from infection after challenge with live virus (14) . A recent report demonstrating protection of these animals against homologous virus challenge for more than 6 months after vaccination with recombinant glycoprotein gp120 leaves questions about the length of this protective immunity (1) . For a vaccine to be effective in humans, it should provide protection for a long period after vaccination. It should also elicit specific cytotoxic T-lymphocyte (CTL) effectors that are able to eliminate cells which are infected by virus that has escaped neutralization, either because of antigenic drift or because of concentrations of antibody inadequate to completely prevent infection. Efforts have thus been focused on studying CTL responses against different HIV proteins; however, only a few epitopes recognized by human CTL clones have been described.
A DR4-restricted gp120 epitope (amino acids [aa] 410 to 429) recognized by CD4+ clones has been identified, but this region is not conserved in other HIV-1 strains (40) . Several * Corresponding author.
epitopes defined by reverse transcriptase-specific CTL clones that were restricted by human leukocyte antigens (HLA) A and B have been reported (50) . Koenig et al. (16) demonstrated an epitope of 10 amino acids (aa 73 to 82) within nef recognized in association with HLA-A3 by a CD8+ CTL clone. The only available information concerning CTL epitopes on gag have been an HLA-B27-restricted epitope on p24gag, analyzed by using bulk stimulated peripheral blood mononuclear cells (PBMC) as effector cells (26) and HLA-A2-restricted epitopes that were described in bulk cultures (5) . In contrast to the envelope glycoprotein, there is less heterogeneity exhibited by the internal viral proteins of sequenced HIV-1 isolates, which makes characterization of T-cell responses of these proteins a priority in view of AIDS vaccine design. In this report, we describe the first CTL response restricted by HLA-Cw3. This HLA antigen is quite common, and this epitope on p24 is highly conserved among HIV-1 strains.
MATERIALS AND METHODS
Recombinant vaccinia viruses and proteins. Vaccinia virus (VAC) and three previously described recombinant vaccinia viruses (VAC/gag, VACIpol, and VAC/gpl60) expressing the gag (48) , reverse transcriptase (50) , and envelope (4) genes of HIV-1 (IIIB strain), respectively, were used to infect target cells for CTL assays.
4052
LITTAUA ET AL. and purified (13a) from Escherichia coli, was also used for the preparation of target cells.
Preparation of synthetic peptides. Synthetic peptides of HIV-1 p249ag were prepared and purified as described previously (11, 29) on the basis of the HIV-1 (III B strain) sequence (34) . The initial peptides tested overlapped with adjacent peptides by 10 or 20 amino acids, and subsequently shorter peptides were prepared and analyzed. The numbering of residues is based on the compilation of Myers et al. (24) .
Preparation , penicillin (100 U/ml), and streptomycin (100 U/ml) and used directly as effector cells in cytotoxicity assays. To obtain T-cell clones, PBMC were seeded at 50 cells per well in 96-well plates with 2 x 105 -y-irradiated normal PBMC from HIV-1-seronegative donors in 0.2 ml of RPMI 1640 containing 10% fetal calf serum, recombinant human interleukin-2 (100 U/ml; Cellular Products, Buffalo, N.Y.), and anti-CD3 antibody 12F6 (0.1 ,ug/ml) as described by Walker et al. (49) . Twice weekly, 0.1 ml of medium was removed from each well and replaced with fresh medium as described above. On day 14, when cell proliferation was observed in all of the wells, cells were transferred to 48-well flat-bottom plates (Costar) and further cultured with 106 y-irradiated allogeneic feeders in 1 ml of the same medium. These cell lines were restimulated every 2 weeks and subsequently used as effector cells in the assay described below.
Cytotoxicity assays. Assays were performed in roundbottom 96-well plates. Various concentrations of effector cells in 0.1 ml of RPMI-10% fetal calf serum were added to 0.1 ml of a 51Cr-labeled target cell suspension (104 cells per ml) in the wells to give the described effector/target (E/T) ratios. After a 6-h incubation at 37°C, the supernatant was harvested from each well and counted in a gamma counter. The assays were performed in triplicate wells, and the percent specific cell lysis was calculated by the formula 100 x (mean experimental release -mean spontaneous release)/ (mean total release -mean spontaneous release after initiation of the culture, the developing clones were screened by testing for HIV-1-specific cytotoxic activity with autologous B-LCL that were uninfected or infected with VAC, VAC/gag, VACIpol, and VAC/gpl6O and with the K562 cell line as a control. Two T-cell clones manifested specificity for HIV-1 envelope (data not shown), and the other clone (clone 165) was gag specific. There was no cytotoxic activity specific for the pol gene product, reverse transcriptase, and lysis of K562 cells was negligible. Phenotypic analysis showed that these cytotoxic clones were CD3+ CD8+ CD4-Leull-(data not shown).
To further analyze antigenic specificity, we examined the ability of the gag-specific CTL clone 165 to lyse target cells pulsed with authentic HIV-1 p24gag protein purified from a recombinant E. coli strain. We observed that clone 165 significantly lysed B-LCL target cells pulsed with purified p24gag protein at levels comparable to the lysis of B-LCL infected with VAC/gag, but they did not lyse uninfected or VAC-infected targets (Fig. 2) . We were unable to evaluate the two env-specific CTL clones from this donor for HLA restriction and epitope mapping because of their limited ability to proliferate in vitro.
Characterization of an HIV-1 gag-specific CTL clone. (i) Determination of the CTL epitope in p249ag. Fourteen overlapping synthetic peptides spanning the p24gag region were used to map the viral epitope recognized by CTL clone 165. As shown in Table 1 , target cells pulsed with either synthetic peptide 1 or 2 were significantly lysed, denoting that the epitope recognized by this clone lies within the overlap region.
The fine specificity of CTL clone 165 was further examined by using truncated peptides corresponding to the first 20-amino-acid sequence of peptide 1 ( Table 2 , experiment A). Targets pulsed with peptides 90-17B and 90-17C lacking the five or seven residues at the N-terminal end of peptide 90-17 were observed to have identical high levels of lysis, whereas targets pulsed with peptides having carboxyl-terminal deletions of four residues from peptide 90-17 were lysed poorly (90-18, -18A, and -18B). Peptide 90-17A, which has the first 13 amino acids of this region deleted, was not recognized by the clone. Additional peptides containing amino acid truncations from the N and C termini revealed 165 , and this inhibition was more apparent when a lower E/T ratio of 2.5:1 was used. The anti-class II MAbs to DP, DQ, and DR (B7/ 21.7, S3/4, and OKIal, respectively) had no effect on the lysis of the target cells by this gag-specific CD8+ T-cell clone (Fig. 3) . The results indicate that this CD8+ T-cell clone lysed target cells in an HLA class I-restricted manner.
The gag-specific clone 165 was also tested for its lytic activity on allogeneic B-LCL target cells infected with VAC/ gag matched at a specific HLA class I locus or unmatched, as indicated in Fig. 4A . The HLA class I alleles of the donor of clone 165 are A3,25, B18, Bw62, and Cw3. This CD8+ clone was able to lyse two allogeneic target cells that shared Cw3 (Fig. 4A) . Since target cells can also be sensitized to virus-specific lysis in vitro by incubation with the appropriate synthetic viral peptide (46), we examined the lysis of other allogeneic targets that had been pulsed with peptide 90-17C, the core peptide which contained the epitope recog- nized by this CTL clone. As shown in Fig. 4B , three of four peptide-sensitized target cells that share Cw3 were lysed. The failure to lyse one target cell that shared Cw3 may be due to variability in HLA alleles, because the HLA determinants which are recognized by the T-cell receptors differ from those defined by typing sera. This has been shown to be true for the HLA-A2 locus, where A2-restricted influenza A virus-specific CTL clones lyse some allogenic target cells sharing an A2 locus but not other targets bearing A2 variants (2, 19) . We were able to confirm the Cw3 restriction of clone 165 by using two transfected P815 (H-2d) mouse mastocytoma cells expressing human HLA-Cw3 that were pulsed with peptide 90-17C in a CTL assay. As shown in Fig. 4C , both cell lines expressing HLA-Cw3 were lysed by clone 165, while P815 control cells pulsed with the same peptide were not lysed. These data clearly show that the epitope on p249ag identified by clone 165 is definitely restricted by Cw3.
DISCUSSION
We described a CD8+ cytotoxic T-cell clone, 165, which recognized an epitope that maps to a 6-amino-acid region (aa 145 to 150) of HIV-1 p249ag. This epitope is located within a region of highly conserved amino acid sequence among various HIV-1 isolates, with most strains (BH10, HXB2, BH5, PV22, HAN, NDK, Z2, BRU, JH3, CDC4, ELI, WMJ, SF2, RF, MN, MAL, and CDC-451) having complete homology and only one isolate (OYI) having an alanine-toproline substitution at position 146 (24) . Interestingly, this HLA-Cw3-restricted CD8+ CTL epitope overlaps B-cell epitopes of p249ag (aa 135 to 149 and 145 to 159) (23) . However, this site would not have been predicted by Berzofsky's amphipathicity algorithm or by any of the widely used computer models (7, 37, 43) . This fact underlines the importance of definitively identifying CTL epitopes by using T-cell clones.
CTL responses to HIV-1 gag protein mediated by CD8-positive HLA class I-restricted T cells have previously been reported (5, 17, 26, 36, 48) . In some studies they were detected in variable degrees in fresh PBMC from HIV-1-infected individuals without in vitro stimulation. Walker et al. (48) reported low gag-specific CTL in three of eight HIV-1-seropositive patients, while Riviere et al. (36) and Koup et al. (17) found gag-specific CTL activity in over 80% of tested HIV-1-seropositive subjects. In the study of Nixon et al. (26) , gag-specific CTL activity was detectable only after in vitro mitogenic stimulation of the cells from HIV-infected individuals.
Despite these bulk culture CTL responses, only a few epitopes have been identified on HIV-1 gag. With use of computer program-predicted gag epitopes, HLA-A2-restricted epitopes were reported by Claverie et al. (5) in bulk culture experiments using four sites within gag different from that detected by clone 165, one of which was conserved. Nixon et al. (26) used phytohemagglutinin-stimulated PBMC of a seropositive donor that had been cultured for 7 days and tested for lytic activity against target cells pulsed with synthetic HIV-1 gag peptides. A CTL epitope restricted by HLA-B27 was defined that comprises aa 265 to 279 and is highly conserved among HIV-1 isolates.
In contrast, sequence variation in the HIV-1 env protein raises concerns associated with their potential use in subunit vaccines based on env alone. For instance, an HLA-DRrestricted gpl20-specific clone directed against an epitope spanning residues 410 to 429 of gp120 demonstrated very limited cross-reactivity against a range of HIV-1 variant peptides (40) . Thus, our results with the p24-specific T-cell clone 165 and those of Nixon et al. (26) suggest that gag sequences that contain highly conserved T-cell epitopes may be very valuable and useful for inclusion in a combination vaccine for HIV.
The isolation of an HIV-1 gag-specific CD8+ T-cell clone from an HIV-1-seropositive and asymptomatic donor is consistent with the gag-specific CTL activity that was obcn CO ci) -J I HLA-C-RESTRICTED CONSERVED CTL EPITOPE ON HIV-1 gag 4055 served in the freshly isolated PBMC. This indicates ongoing antigenic stimulation in vivo since this cytotoxic activity was detected directly in fresh blood and continued to be detected in the cultured lymphocytes without in vitro HIV-1 antigenic stimulation. This T-cell clone has demonstrated a persistent gag-specific cytotoxic activity for the last 14 months and is presumably not polyclonal since it recognizes a single small peptide.
The highly conserved epitope on HIV-1 p24 is recognized by the CD8+ clone 165 in an HLA-Cw3-restricted manner. It has been assumed that HLA-C major histocompatible antigens function similarly to the structurally related HLA-A and -B antigens (13) . This is the first report to our knowledge that HLA-C antigens are restrictive elements for human CTL, although it has been demonstrated recently that transgenic mice expressing the HLA-Cw3 gene developed CTL responses to influenza and Sendai viruses which were Cw3 restricted (9) . Cw3 is found in 20% of Caucasians and blacks, 62% of Native Americans, and 47% of Asians, and thus it is a common HLA allele (45) .
In general, CTLs can eliminate virus-infected cells, as has been proven by the recovery from acute infections with viruses such as influenza virus (20) (21) (22) , lymphocytic choriomeningitis virus (3), cytomegalovirus (33, 35) , varicellazoster virus (41, 42) , and herpes simplex virus (25, 27) and in persistent (lymphocytic choriomeningitis virus) infections (28) . Whether the role played by these CTLs is deleterious (18, 32, 38, 39) or helpful to the HIV-infected host is unclear. Their beneficial role is suggested by studies showing that the level of CD8+ CTL detected in the blood of antibodypositive HIV-1-infected individuals appears to decrease with disease progression (30, 31) , and this parallels the loss of HIV-1-specific cytotoxicity (47) . Others have shown that CD8+ lymphocytes isolated from HIV-infected individuals and simian immunodeficiency virus-infected macaques suppress HIV replication in vitro, although the mechanism of antiviral activity remains to be defined (15, 51) . It has also been shown that synthetic viral lipopeptides can efficiently prime animals for MHC class I-restricted CTL responses (8) .
While the biologic relevance of human CTLs in HIV-1 infections is not certain, data in animal systems indicate that they are likely to be important. Thus, there is a necessity to collect a wide data base of highly conserved epitopes. If it is shown that CTL responses to conserved epitopes provide protection in primate models against disease, it may be useful to combine several cross-reactive defined epitopes that may induce protection in the majority of individuals against HIV-1 disease.
